引用本文:侯少东,严存晔,殷素鹏,孙乙曾,张 帆.甲状腺乳头状癌TERT启动子突变与颈部淋巴结转移关系的Meta分析[J].中国临床新医学,2023,16(8):778-783.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 629次   下载 907 本文二维码信息
码上扫一扫!
分享到: 微信 更多
甲状腺乳头状癌TERT启动子突变与颈部淋巴结转移关系的Meta分析
侯少东,严存晔,殷素鹏,孙乙曾,张 帆
637000 南充,川北医学院(侯少东,张 帆);401147 重庆,重庆市人民医院乳腺甲状腺外科(侯少东,严存晔,殷素鹏,孙乙曾,张 帆)
摘要:
[摘要] 目的 采用Meta分析评价甲状腺乳头状癌患者端粒酶逆转录酶启动子(TERTp)突变与颈部淋巴结转移之间的关系。方法 检索PubMed、the Cochrane Library、Embase数据库、Web of Science、中国知网数据库、万方全文数据库,搜集甲状腺乳头状癌患者携带TERTp突变的病例对照研究或队列研究,检索截至2023年7月。由2名研究者独立筛选文献、提取资料并评价纳入研究的偏倚风险后,使用Review Manager 5.4和STATA 17.0进行Meta分析。结果 共检出文献369篇,最终纳入33项研究,包括12 683例患者。Meta分析表明,携带TERTp突变的PTC患者较未发生TERTp突变的PTC患者,发生颈部淋巴结转移的风险更高。结论 TERTp突变会增加PTC患者颈部淋巴结转移风险,是预测PTC患者发生淋巴结转移的重要参考因素。
关键词:  甲状腺乳头状癌  端粒酶逆转录酶启动子  颈部淋巴结转移  Meta分析
DOI:10.3969/j.issn.1674-3806.2023.08.04
分类号:R 736.1
基金项目:重庆市技术创新与应用发展专项重点项目(编号:CSTB2022TIAD-KPX0177)
Evaluation of the relationship between TERT promoter mutation and cervical lymph node metastasis in papillary thyroid carcinoma: a meta-analysis
HOU Shao-dong, YAN Cun-ye, YIN Su-peng, et al.
North Sichuan Medical College, Nanchong 637000, China; Department of Breast and Thyroid Surgery, Chongqing General Hospital, Chongqing 401147, China
Abstract:
[Abstract] Objective To evaluate the relationship between telomerase reverse transcriptase promoter(TERTp) mutation and cervical lymph node metastasis in patients with papillary thyroid carcinoma(PTC) by meta-analysis. Methods Case-control or cohort studies of TERTp mutations in PTC patients were electronically searched from PubMed, the Cochrane Library, Embase, Web of Science, China National Knowledge Internet(CNKI) and Wanfang databases up to July 2023. Two reviewers independently screened the literature, from which the data were extracted and assessed the risk of bias of the included studies. Review Manager 5.4 and STATA 17.0 were used for meta-analysis. Results A total of 369 papers were retrieved, and 33 studies were finally included, including 12 683 patients.The meta-analysis showed that the PTC patients carrying TERTp mutations had a higher risk of cervical lymph node metastasis than those without TERTp mutations. Conclusion TERTp mutation increases the risk of cervical lymph node metastasis in PTC patients and is an important reference factor in predicting lymph node metastasis in the PTC patients.
Key words:  Papillary thyroid carcinoma(PTC)  Telomerase reverse transcriptase promoter(TERTp)  Cervical lymph node metastasis  Meta-analysis